Nesiritide
FDA approved · RxRecombinant natriuretic peptide
Also known as: Natrecor, BNP, nesiritida, nesiritidum, Nesiritide Recombinant, Human Brain Natriuretic Factor-32
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 289 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP), a hormone normally released by the heart's ventricles. It binds natriuretic peptide receptors, raising cyclic GMP, which relaxes blood vessels and promotes sodium and water excretion. It was marketed under the brand name Natrecor as an intravenous hospital medicine.
What the evidence shows
Nesiritide was approved for the treatment of acutely decompensated heart failure with shortness of breath, and it has been studied in hundreds of registered trials, including Phase 4. Large trials such as ASCEND-HF found it modestly eased breathlessness but did not improve survival or rehospitalization. The facts provided here did not confirm a current FDA listing, and the product has reportedly been discontinued in the US, so its present availability is unclear.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Circulatory Function in Laparoscopic Radical Cystectomy for Bladder Cancer
Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
Predictive Value of Dynamic Combination of BNP and NGAL for the Prognosis of Patients With Sepsis
A Health Economic Evaluation of Using N-Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) in Acute Heart Failure
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Effect of nesiritide in patients with acute decompensated heart failure.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.
B-type natriuretic peptide in cardiovascular disease.
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
Sources
- PubChem compound record (CID 71308561)
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.